Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?

Noer, Mette Calundann; Sperling, Cecilie Dyg; Ottesen, Bent; Antonsen, Sofie Leisby; Christensen, Ib Jarle; Høgdall, Claus

doi:10.1097/igc.0000000000001001

Cited by 13 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have suggested that patients might fear that prolonged treatment delay results in poorer oncological outcome (Agasi-Idenburg et al, 2019;Curtis et al, 2018;Strous et al, 2019). However, studies concerning treatment delays among CRC and OC patients did not find a negative impact on survival (Noer et al, 2017;Strous et al, 2019). Thus, some studies conclude that there is a safe window for prehabilitation, meaning that the preoperative period could be expanded, without jeopardising outcomes (Curtis et al, 2018;Strous et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

What matters to you? An investigation of patients’ perspectives on and acceptability of prehabilitation in major cancer surgery

et al. 2021

View full text Add to dashboard Cite

Prehabilitation refers to the process of making patients fit for surgery with the aim of enabling them to withstand treatment-related stress (Topp et al., 2002). The last decade prehabilitation interventions in patients with cancer have attracted attention, owing to a growing body of evidence indicating beneficial effects on postoperative outcomes (Scheede-Bergdahl et al., 2019). However, in particular, prehabilitation in cancer care represents a challenge, as newly diagnosed cancer patients are going through a stressful and life-changing period of time prior to surgery that often entails feelings such as shock, fear, anger, confusion and powerlessness

show abstract

Section: Discussionmentioning

confidence: 99%

What matters to you? An investigation of patients’ perspectives on and acceptability of prehabilitation in major cancer surgery

et al. 2021

View full text Add to dashboard Cite

show abstract

“…During the course of treatment of ovarian cancer, several complications can develop 7 . In most cases, there is no notable effect; however, some complications, such as cardiopulmonary complications and/or infection, can delay the standard cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea

et al. 2021

View full text Add to dashboard Cite

Background Venous thromboembolism (VTE) is a hospital‐associated severe complication that may adversely affect patient prognosis. In this study, we evaluated the incidence of VTE and its risk factors in patients with epithelial ovarian cancer (EOC). Methods We retrospectively analyzed the electronic health record data of 1268 patients with EOC who received primary treatment at the National Cancer Center, Korea between January 2007 and December 2017 to identify patients who developed VTE. Demographic, clinical, and surgical characteristics of these patients were ascertained. Competing risks analyses were performed to estimate the cumulative incidence of VTE according to the treatment type. The associations between putative risk factors and the incidence of VTE were evaluated using the Fine–Gray regression models accounting for competing risks of death. Results VTE was the most prevalent cardiovascular event, found in 9.6% (n = 122) of all patients. Of these VTE events, 115 (94.3%) occurred within 2 years of EOC diagnosis. Advanced cancer stage at diagnosis (distant vs. localized, hazards ratio [HR])= 14.49, p = 0.015) and extended hospital stay (≥15 days, HR =3.87, p = 0.004) were associated with the incidence of VTE. There was no significant difference in the cumulative incidence of VTE between primary cytoreductive surgery followed by adjuvant chemotherapy and neoadjuvant chemotherapy followed by interval cytoreductive surgery (HR =0.81, p = 0.390). Conclusions Approximately 10% of patients with EOC were diagnosed with VTE, which was the most common cardiovascular disease found in this study. The assessment of VTE risks in patients with advanced‐stage EOC with an extended hospital stay is needed to facilitate adequate prophylactic treatment.

show abstract

“…In advanced ovarian cancer, it has been consistently demonstrated that optimal surgical cytoreduction is crucial to improving outcomes [ 78 – 80 ]. While some small reports have demonstrated that treatment delays do not significantly impact survival and have even correlated with improved survival, these are largely due to medical comorbidities or significant age differences of the patient population [ 81 ]. Patients with significant comorbidities or advanced age often need a longer time to recover from neoadjuvant therapy or for surgical optimization.…”

Section: Resultsmentioning

confidence: 99%

What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer

Savage

Lesher

Abbott

et al. 2020

COR

View full text Add to dashboard Cite

Background: The impact of the COVID-19 pandemic has spread beyond those infected with SARS-CoV2. Its widespread consequences have affected cancer patients whose surgeries may be delayed in order to minimize exposure and conserve resources. Methods: Experts in each surgical oncology subspecialty were selected to perform a review of the relevant literature. Articles were obtained through PubMed searches in each cancer subtype using the following terms: delay to surgery, time to surgery, outcomes, and survival. Results: Delays in surgery > 4 weeks in breast cancer, ductal carcinoma in situ, T1 pancreatic cancer, ovarian cancer, and pediatric osteosarcoma, negatively impacted survival. Studies on hepatocellular cancer, colon cancer, and melanoma (Stage I) demonstrated reduced survival with delays > 3 months. Conclusion: Studies have shown that short-term surgical delays can result in negative impacts on patient outcomes in multiple cancer types as well as in situ carcinoma. Conversely, other cancers such as gastric cancer, advanced melanoma and pancreatic cancer, well-differentiated thyroid cancer, and several genitourinary cancers demonstrated no significant outcome differences with surgical delays.

show abstract

Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?

Cited by 13 publications

References 23 publications

What matters to you? An investigation of patients’ perspectives on and acceptability of prehabilitation in major cancer surgery

What matters to you? An investigation of patients’ perspectives on and acceptability of prehabilitation in major cancer surgery

Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea

What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer

Contact Info

Product

Resources

About